Yang Li, Guo Jiongchao, Chen Min, Wang Yuqi, Li Jun, Zhang Jing
Department of Cardiology, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, 230011 Hefei, Anhui, China.
The Fifth Clinical School of Medicine, Anhui Medical University, 230000 Hefei, Anhui, China.
Rev Cardiovasc Med. 2024 Aug 20;25(8):294. doi: 10.31083/j.rcm2508294. eCollection 2024 Aug.
The inflammatory response to atherosclerosis is a process that leads to coronary artery disease. Pan-immune-inflammation value (PIV) has emerged as a new and simple biomarker of inflammation. However, studies on the predictive power of PIV for major adverse cardiovascular events (MACE) or the degree of coronary artery stenosis are scarce. We aimed to explore the predictive ability of PIV for MACE and the degree of coronary artery stenosis in patients with ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI) during hospitalization.
This study included 542 patients who were diagnosed with STEMI and who underwent PCI between 2016 and 2023 and whose PIV and other inflammatory markers were measured. Using univariate and multivariate logistic regression analysis, risk variables for MACE following PCI and severe coronary stenosis during hospitalization were assessed to create receiver operating characteristic (ROC) curves and determine the best thresholds for inflammatory markers. Spearman correlation analysis was used to evaluate the correlation of PIV and other inflammatory markers with the Gensini score (GS).
Compared with the systemic inflammatory index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), the PIV may have greater predictive value in terms of the occurrence of MACE and the degree of coronary stenosis after PCI in hospitalized STEMI patients. The correlation between the PIV and GS was strong.
PIV was superior to the SII, PLR, and NLR in predicting inpatient prognosis and severe coronary stenosis after PCI for STEMI patients.
动脉粥样硬化的炎症反应是导致冠状动脉疾病的一个过程。全免疫炎症值（PIV）已成为一种新的、简单的炎症生物标志物。然而，关于PIV对主要不良心血管事件（MACE）或冠状动脉狭窄程度的预测能力的研究较少。我们旨在探讨PIV对ST段抬高型心肌梗死（STEMI）患者经皮冠状动脉介入治疗（PCI）后住院期间MACE及冠状动脉狭窄程度的预测能力。
本研究纳入了542例在2016年至2023年间被诊断为STEMI并接受PCI治疗且测量了PIV和其他炎症标志物的患者。采用单因素和多因素逻辑回归分析，评估PCI后MACE及住院期间严重冠状动脉狭窄的风险变量，以绘制受试者工作特征（ROC）曲线并确定炎症标志物的最佳阈值。采用Spearman相关性分析评估PIV和其他炎症标志物与Gensini评分（GS）的相关性。
与全身炎症指数（SII）、血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）相比，PIV在预测住院STEMI患者PCI后MACE的发生及冠状动脉狭窄程度方面可能具有更大的预测价值。PIV与GS之间的相关性很强。
在预测STEMI患者PCI后的住院预后和严重冠状动脉狭窄方面，PIV优于SII、PLR和NLR。
